New drug cocktail shows promise against rare blood cancer
NCT ID NCT01559935
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 30 times
Summary
This study tested a combination of four drugs (carfilzomib, clarithromycin, lenalidomide, and dexamethasone) in 74 adults with newly diagnosed multiple myeloma, a type of blood cancer. The goal was to see how well the treatment worked and if it was safe. Patients received the drugs in a specific order, and the best response was measured using standard criteria. While the treatment aims to control the disease, patients may need ongoing therapy, so it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medical College
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.